ClinicalTrials.gg
CompletedNCT04963231Updated Jul 2, 2025Results posted

DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) Pathway

A Phase 2 interventional study of Setmelanotide and Placebo in Genetic Obesity, sponsored by Rhythm Pharmaceuticals, Inc.. Completed at 36 sites in 8 countries. Open to participants aged 6 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-07-02.

Sponsored by Rhythm Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
164
Allocation
Randomized
Ages
6 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing setmelanotide in Obesity — 1 open to participants now, 2 under way, none of them phase 3. setmelanotide · Obesity.

Enrollment
4th of 16
164 · median 34
Started
2021
the only one that year
Phase 2
6 of 16
1 open now
Registered
12th of 16
by date
Lead sponsor
15 of 16
Rhythm Pharmaceuticals, Inc.

Among the 16 studies testing setmelanotide in Obesity, this one is the 4th largest by enrollment, is the only one that started in 2021, is one of 6 in phase 2, and was the 12th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

1 of the 16 studies testing setmelanotide in Obesity is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About setmelanotide

setmelanotide: first FDA approval 2020 (IMCIVREE), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 6 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing setmelanotide in Obesity, or all of them as a file.
02

Study summary

The purpose of this study was to evaluate the safety and efficacy of once daily subcutaneous (SC) administration of setmelanotide in participants with obesity and specific gene variants in the MC4R pathway.

03

Conditions studied

  • Genetic Obesity

Browse trials for

Keywords

  • Melanocortin-4 Receptor
  • Genetic Obesity
  • Leptin
04

Who can participate

Ages eligible
6 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Participants must have had a pre-identified genetic variant in an established MC4R pathway gene that contributes to obesity
  • Age 6 to 65 years, inclusive
  • Obesity, defined as (BMI) ≥40 kilograms per square meter (kg/m\^2) for participants ≥18 years of age or BMI ≥97th percentile for age and gender for participants 6 to \<18 years of age
  • Study participant and/or parent or guardian were able to understand all study procedures and provide consent/assent
  • Use of highly effective
  • Symptoms or behaviors of hyperphagia

Key Exclusion Criteria:

  • Participants with the following genetic variants: biallelic Bardet-Biedl Syndrome (BBS); biallelic Alström Syndrome 1 (ALMS1); homozygous, heterozygous, or compound heterozygous variants in MC4R, Pro-opiomelanocortin (POMC), Proprotein convertase subtilisin/kexin type 1 (PCSK1), Leptin receptor (LEPR), nuclear receptor coactivator 1 (NCOA1; receptor coactivator-1 [SRC1]) or SRC homology 2 B adapter protein 1 (SH2B1) genes as well as 16p11.2 chromosomal deletions that included the SH2B1 gene
  • Recent intensive diet and/or exercise regimen with or without the use of weight loss agents including herbal medications that had resulted in weight loss >2% within previous 3 months
  • Bariatric surgery within the previous 6 months
  • Documented diagnosis of current unstable major psychiatric disorder or a documented worsening of psychiatric condition that required changes in treatment within 2 years
  • Any suicidal ideation of type 4 or 5 on the Columbia-Suicide Severity Rating Scale (C-SSRS) or Patient Health Questionnaire 9 (PHQ 9) score of ≥15 during Screening, any suicide attempt in participant's lifetime years, or any suicidal behavior in the last month.
  • Current, pulmonary, cardiac, or oncologic disease considered severe enough to interfere with the study
  • Has significant features of (or meets the diagnostic criteria for) a genetic syndrome that is associated with obesity
  • (HbA1C) >10.0% at Screening
  • History of significant liver disease
  • (GFR) \<30 milliliter per minute (mL/min) at Screening
  • History or close family history of melanoma or participant history of oculocutaneous albinism
  • Significant dermatologic findings relating to melanoma or pre-melanoma skin lesions
  • Participation in any clinical study with an drug/device within 3 months prior to the first day of dosing
  • Participants previously enrolled in a clinical study involving setmelanotide or any previous exposure to setmelanotide
  • Significant to any in the study drug
  • Females who were breastfeeding or nursing

Other protocol defined Inclusion/Exclusion criteria applied.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
164 participants (actual)

Study arms

  • Experimental
    Stage 1: Setmelanotide (Open-Label)

    Participants received once daily SC injection of setmelanotide from Day 1 to Week 16 in an open-label treatment stage (Stage 1). Participants ≥12 years of age started on setmelanotide 2.0 milligrams (mg) once daily for approximately 2 weeks, then increased to 3.0 mg once daily. Participants \<12 years of age started on setmelanotide 1.0 mg once daily for approximately 1 week, then increased to 2.0 mg once daily for approximately 1 week, then increased to 3.0 mg once daily.

    Drug: Setmelanotide

  • Experimental
    Stage 2: Setmelanotide (Double-Blind)

    Participants from Stage 1 who were eligible for Stage 2 received once daily SC injection of setmelanotide 3.0 mg from Week 16 to Week 40 in a double-blind treatment Stage (Stage 2).

    Drug: Setmelanotide

  • Placebo comparator
    Stage 2: Placebo (Double-Blind)

    Participants from Stage 1 who were eligible for Stage 2 received once daily SC injection of matching placebo 3.0 mg from Week 16 to Week 40 in a double-blind treatment Stage (Stage 2).

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Stage 1: Number of Participants by Genotype Who Demonstrated a Significant Clinically Meaningful Response to Setmelanotide at the End of Stage 1

    BMI was calculated using participant's weight and height assessments, using the following formula: BMI = Kilogram (kg)/ square meter (m\^2). A significant clinically meaningful response was defined as achieving a ≥5% reduction in BMI from Baseline. Data are provided for overall and according to participants with specified primary gene. Baseline was defined as the last available measurement taken prior to the start of treatment Stage 1 administration.

    Time frame: Baseline to Week 16

Secondary outcomes

  1. Mean Change in BMI From Baseline to the End of Stage 1 in All Participants, Per Genotype

    BMI was calculated using participant's weight and height assessments, using the following formula: BMI = kg/m\^2. Data are provided for overall and according to participants with specified primary gene. Baseline was defined as the last available measurement taken prior to the start of treatment Stage 1 administration.

    Time frame: Baseline, Week 16

  2. Mean Change in BMI From Baseline to the End of Stage 1 in Participants ≥18 Years Old, Per Genotype

    BMI was calculated using participant's weight and height assessments, using the following formula: BMI = kg/m\^2 Data are provided for overall and according to participants with specified primary gene. Baseline was defined as the last available measurement taken prior to the start of treatment Stage 1 administration.

    Time frame: Baseline, Week 16

  3. Percent Change in BMI From Baseline to the End of Stage 1 in All Participants, Per Genotype

    BMI was calculated using participant's weight and height assessments, using the following formula: BMI = kg/m\^2 Data are provided for overall and according to participants with specified primary gene. Baseline was defined as the last available measurement taken prior to the start of treatment Stage 1 administration.

    Time frame: Baseline, Week 16

  4. Percent Change in BMI From Baseline to the End of Stage 1 in Participants ≥18 Years Old, Per Genotype

    BMI was calculated using participant's weight and height assessments, using the following formula: BMI = kg/m\^2 Data are provided for overall and according to participants with specified primary gene. Baseline was defined as the last available measurement taken prior to the start of treatment Stage 1 administration.

    Time frame: Baseline, Week 16

  5. Mean Change in Body Weight From Baseline to the End of Stage 1 in Participants ≥18 Years Old, Per Genotype

    Data are provided for overall and according to participants with specified primary gene. Baseline was defined as the last available measurement taken prior to the start of treatment Stage 1 administration.

    Time frame: Baseline, Week 16

  6. Percent Change in Body Weight From Baseline to the End of Stage 1 in Participants ≥18 Years Old, Per Genotype

    Data are provided for overall and according to participants with specified primary gene. Baseline was defined as the last available measurement taken prior to the start of treatment Stage 1 administration.

    Time frame: Baseline, Week 16

  7. Mean Change in BMI Z-score From Baseline to the End of Stage 1 in Participants <18 Years Old, Per Genotype

    BMI was calculated using participant's weight and height assessments, using the following formula: BMI = kg/m\^2. The BMI Z-score indicated the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean of a reference population (i.e., healthy, age and sex-matched individuals). A decrease of BMI Z-score indicates a reduction in BMI from Baseline whereas an increase of BMI-Z score indicates an increase in BMI from Baseline. Baseline was defined as the last available measurement taken prior to the start of treatment Stage 1 administration.

    Time frame: Baseline, Week 16

  8. Percent Change in the Weekly Average of the Daily Maximal Hunger Score From Baseline to the End of Stage 1 in Participants ≥12 Years Old, Per Genotype

    Daily Hunger Questionnaire for participants ≥12 years of age is self-administered questionnaire and comprises three items. For the assessment of this endpoint, maximal hunger was corresponding to the following question: In the last 24 hours, how hungry did you feel when you were the most hungry? The response was scored separately and averaged on weekly basis. Participants rated their hunger on an 11-point numeric rating scale ranging from 0 to 10 (0 = not hungry at all, and 10 = hungriest possible). Weekly average at Week 16 was defined as average of the available score values within 7 days in Week 16. Baseline was defined as the average of the available score values within 7 days before or on the stage 1 open-label treatment. Results are reported by overall participant results and by specific gene cohort.

    Time frame: Baseline, Week 16

  9. Number of Participants ≥12 Years Old, Who Achieved a ≥2 Point Reduction From Baseline to the End of Stage 1 in the Weekly Average of the Daily Maximal Hunger Score, Per Genotype

    Daily Hunger Questionnaire for participants ≥12 years of age is self-administered questionnaire and comprises three items. For the assessment of this endpoint, maximal hunger was corresponding to the following question: In the last 24 hours, how hungry did you feel when you were the most hungry? The response was scored separately and averaged on weekly basis. Participants rated their hunger on an 11-point numeric rating scale ranging from 0 to 10 (0 = not hungry at all, and 10 = hungriest possible). Weekly average at Week 16 was defined as average of the available score values within 7 days in Week 16. Baseline was defined as the average of the available score values within 7 days before or on the stage 1 open-label treatment. Results are reported by overall participant results and by specific gene cohort.

    Time frame: Baseline, Week 16

07

Results

Posted Oct 24, 2024

Participant flow

Stage 1 (Open-Label, Duration: 16 Weeks)
Participant flow — Stage 1 (Open-Label, Duration: 16 Weeks)
MilestoneStage 1: Setmelanotide (Open-Label)Stage 2: Setmelanotide (Double-Blind)Stage 2: Placebo (Double-Blind)
Started16400
Completed10000
Not completed6400
Withdrew: Adverse event4300
Withdrew: Protocol violation300
Withdrew: Withdrawal by subject1600
Withdrew: Lost to follow-up200
Stage 2 (Double-Blind, Duration:24 Week)
Participant flow — Stage 2 (Double-Blind, Duration:24 Week)
MilestoneStage 1: Setmelanotide (Open-Label)Stage 2: Setmelanotide (Double-Blind)Stage 2: Placebo (Double-Blind)
Started03217
Safety analysis set enrolled in stage 203514
Completed02910
Not completed037
Withdrew: Adverse event001
Withdrew: Withdrawal by subject022
Withdrew: Other than specified014

Outcome measures

PrimaryStage 1: Number of Participants by Genotype Who Demonstrated a Significant Clinically Meaningful Response to Setmelanotide at the End of Stage 1

BMI was calculated using participant's weight and height assessments, using the following formula: BMI = Kilogram (kg)/ square meter (m\^2). A significant clinically meaningful response was defined as achieving a ≥5% reduction in BMI from Baseline. Data are provided for overall and according to participants with specified primary gene. Baseline was defined as the last available measurement taken prior to the start of treatment Stage 1 administration.

Time frame:
Baseline to Week 16
Reported as:
Count of participants · Participants
Stage 1: Number of Participants by Genotype Who Demonstrated a Significant Clinically Meaningful Response to Setmelanotide at the End of Stage 1
ParticipantsStage 1: Setmelanotide (Open-Label)
Overall49
Gene: NRP10
Gene: NRP20
Gene: PLXNA12
Gene: PLXNA23
Gene: PLXNA32
Gene: PLXNA45
Gene: SEMA3A2
Gene: SEMA3B1
Gene: SEMA3C0
Gene: SEMA3D0
Gene: SEMA3E3
Gene: SEMA3F2
Gene: SEMA3G8
Gene: PHIP9
Gene: SIM15
Gene: MAGEL23
Gene: CREBBP0
Gene: DNMT3A0
Gene: HTR2C0
Gene: KSR21
Gene: MRAP20
Gene: RPGRIP1L1
Gene: TBX32
Gene: TRPC50
SecondaryMean Change in BMI From Baseline to the End of Stage 1 in All Participants, Per Genotype

BMI was calculated using participant's weight and height assessments, using the following formula: BMI = kg/m\^2. Data are provided for overall and according to participants with specified primary gene. Baseline was defined as the last available measurement taken prior to the start of treatment Stage 1 administration.

Time frame:
Baseline, Week 16
Reported as:
Mean · Kg/m^2
Mean Change in BMI From Baseline to the End of Stage 1 in All Participants, Per Genotype
Kg/m^2Stage 1: Setmelanotide (Open-Label)
Overall: At Baseline45.338 ± 9.5526
Overall: Change at Week 16-1.916 ± 1.7971
Gene: NRP1, At Baseline48.601 ± 2.7893
Gene: NRP1, Change at Week 160.229 ± 1.6024
Gene: NRP2, At Baseline46.568 ± 10.6754
Gene: NRP2, Change at Week 16-1.040 ± 0.8650
Gene: PLXNA1, At Baseline45.576 ± 5.5644
Gene: PLXNA1, Change at Week 16-1.884 ± 1.8912
Gene: PLXNA2, At Baseline48.577 ± 12.1795
Gene: PLXNA2, Change at Week 16-2.492 ± 2.0273
Gene: PLXNA3, At Baseline34.083 ± 6.4705
Gene: PLXNA3, Change at Week 16-3.333 ± 0.5166
Gene: PLXNA4, At Baseline46.634 ± 8.5714
Gene: PLXNA4, Change at Week 16-2.218 ± 2.9947
Gene: SEMA3A, At Baseline39.405 ± 7.8242
Gene: SEMA3A, Change at Week 16-2.328 ± 0.2612
Gene: SEMA3B, At Baseline42.890 ± 5.0100
Gene: SEMA3B, Change at Week 16-2.557
Gene: SEMA3C, At Baseline47.543
Gene: SEMA3C, Change at Week 16-2.334
Gene: SEMA3D, At Baseline45.814 ± 5.7690
Gene: SEMA3D, Change at Week 16-1.638 ± 0.6445
Gene: SEMA3E, At Baseline43.005 ± 1.6275
Gene: SEMA3E, Change at Week 16-3.132 ± 2.4180
Gene: SEMA3F, At Baseline54.979 ± 15.1825
Gene: SEMA3F, Change at Week 16-3.556 ± 1.1758
Gene: SEMA3G, At Baseline44.464 ± 8.4848
Gene: SEMA3G, Change at Week 16-2.124 ± 1.5203
Gene: PHIP, At Baseline40.808 ± 10.0222
Gene: PHIP, Change at Week 16-2.120 ± 1.0108
Gene: SIM1, At Baseline47.729 ± 9.7294
Gene: SIM1, Change at Week 16-1.698 ± 1.8931
Gene: MAGEL2, At Baseline42.047 ± 8.2605
Gene: MAGEL2, Change at Week 16-1.637 ± 1.3549
Gene: CREBBP, At Baseline47.490
Gene: CREBBP, Change at Week 160.165
Gene: DNMT3A, At Baseline44.138
Gene: DNMT3A, Change at Week 16-1.080
Gene: HTR2C, At Baseline52.105 ± 3.0212
Gene: HTR2C, Change at Week 16-1.381
Gene: KSR2, At Baseline47.624 ± 11.4457
Gene: KSR2, Change at Week 16-1.073 ± 1.4410
Gene: MRAP2, At Baseline58.100
Gene: MRAP2, Change at Week 16-1.470
Gene: RPGRIP1L, At Baseline43.442 ± 2.6778
Gene: RPGRIP1L, Change at Week 16-3.603
Gene: TBX3, At Baseline40.170 ± 10.5867
Gene: TBX3, Change at Week 16-1.951 ± 1.3582
Gene: TRPC5, At Baseline49.974 ± 24.5155
Gene: TRPC5, Change at Week 160.161 ± 1.2979
SecondaryMean Change in BMI From Baseline to the End of Stage 1 in Participants ≥18 Years Old, Per Genotype

BMI was calculated using participant's weight and height assessments, using the following formula: BMI = kg/m\^2 Data are provided for overall and according to participants with specified primary gene. Baseline was defined as the last available measurement taken prior to the start of treatment Stage 1 administration.

Time frame:
Baseline, Week 16
Reported as:
Mean · Kg/m^2
Mean Change in BMI From Baseline to the End of Stage 1 in Participants ≥18 Years Old, Per Genotype
Kg/m^2Stage 1: Setmelanotide (Open-Label)
Overall: At Baseline48.464 ± 8.0877
Overall: Change at Week 16-1.872 ± 1.8963
Gene: NRP2, At Baseline51.640 ± 8.5762
Gene: NRP2, Change at Week 16-0.783 ± 1.0489
Gene: PLXNA1, At Baseline46.959 ± 6.2279
Gene: PLXNA1, Change at Week 16-0.678 ± 0.8796
Gene: PLXNA2, At Baseline50.335 ± 12.3004
Gene: PLXNA2, Change at Week 16-2.324 ± 0.6565
Gene: PLXNA3, At Baseline40.801
Gene: PLXNA3, Change at Week 16-3.698
Gene: PLXNA4, At Baseline48.420 ± 7.4340
Gene: PLXNA4, Change at Week 16-2.532 ± 3.1514
Gene: SEMA3A, At Baseline47.366
Gene: SEMA3A, Change at Week 16-2.513
Gene: SEMA3B, At Baseline43.320
Gene: SEMA3D, At Baseline47.296 ± 6.0613
Gene: SEMA3D, Change at Week 16-1.638 ± 0.6445
Gene: SEMA3E, At Baseline42.004 ± 1.1954
Gene: SEMA3E, Change at Week 16-4.716 ± 0.0565
Gene: SEMA3F, At Baseline64.964 ± 9.9946
Gene: SEMA3F, Change at Week 16-4.388
Gene: SEMA3G, At Baseline46.762 ± 6.5047
Gene: SEMA3G, Change at Week 16-2.302 ± 1.6478
Gene: PHIP, At Baseline45.343 ± 7.0089
Gene: PHIP, Change at Week 16-2.110 ± 1.1464
Gene: SIM1, At Baseline50.790 ± 8.9593
Gene: SIM1, Change at Week 16-1.465 ± 1.7916
Gene: MAGEL2, At Baseline46.198 ± 5.0997
Gene: MAGEL2, Change at Week 16-1.191 ± 1.0137
Gene: CREBBP, At Baseline47.490
Gene: CREBBP, Change at Week 160.165
Gene: DNMT3A, At Baseline44.138
Gene: DNMT3A, Change at Week 16-1.080
Gene: HTR2C, At Baseline52.105 ± 3.0212
Gene: HTR2C, Change at Week 16-1.381
Gene: KSR2, At Baseline51.397 ± 9.2011
Gene: KSR2, Change at Week 16-0.792 ± 1.5759
Gene: RPGRIP1L, At Baseline43.442 ± 2.6778
Gene: RPGRIP1L, Change at Week 16-3.603
Gene: TBX3, At Baseline44.494 ± 4.3444
Gene: TBX3, Change at Week 16-0.705
Gene: TRPC5, At Baseline62.246 ± 17.2758
Gene: TRPC5, Change at Week 160.161 ± 1.2979
SecondaryPercent Change in BMI From Baseline to the End of Stage 1 in All Participants, Per Genotype

BMI was calculated using participant's weight and height assessments, using the following formula: BMI = kg/m\^2 Data are provided for overall and according to participants with specified primary gene. Baseline was defined as the last available measurement taken prior to the start of treatment Stage 1 administration.

Time frame:
Baseline, Week 16
Reported as:
Mean · percent change
Percent Change in BMI From Baseline to the End of Stage 1 in All Participants, Per Genotype
percent changeStage 1: Setmelanotide (Open-Label)
Overall: Change at Week 16-4.62 ± 4.394
Gene: NRP1, Change at Week 160.57 ± 3.329
Gene: PLXNA1, Change at Week 16-4.00 ± 4.296
Gene: NRP2, Change at Week 16-2.33 ± 2.105
Gene: PLXNA2, Change at Week 16-4.90 ± 3.909
Gene: PLXNA3, Change at Week 16-8.95 ± 0.156
Gene: PLXNA4, Change at Week 16-5.00 ± 6.577
Gene: SEMA3A, Change at Week 16-5.39 ± 0.123
Gene: SEMA3B, Change at Week 16-6.79
Gene: SEMA3C, Change at Week 16-4.91
Gene: SEMA3D, Change at Week 16-3.57 ± 1.960
Gene: SEMA3E, Change at Week 16-7.39 ± 5.752
Gene: SEMA3F, Change at Week 16-7.66 ± 0.119
Gene: SEMA3G, Change at Week 16-5.09 ± 3.284
Gene: PHIP, Change at Week 16-6.12 ± 3.623
Gene: SIM1, Change at Week 16-4.02 ± 5.310
Gene: MAGEL2, Change at Week 16-4.60 ± 4.288
Gene: CREBBP, Change at Week 160.35
Gene: DNMT3A, Change at Week 16-2.45
Gene: HTR2C, Change at Week 16-2.49
Gene: KSR2, Change at Week 16-2.15 ± 2.928
Gene: MRAP2, Change at Week 16-2.53
Gene: RPGRIP1L, Change at Week 16-8.64
Gene: TBX3, Change at Week 16-6.41 ± 5.011
Gene: TRPC5, Change at Week 16-0.03 ± 2.094
SecondaryPercent Change in BMI From Baseline to the End of Stage 1 in Participants ≥18 Years Old, Per Genotype

BMI was calculated using participant's weight and height assessments, using the following formula: BMI = kg/m\^2 Data are provided for overall and according to participants with specified primary gene. Baseline was defined as the last available measurement taken prior to the start of treatment Stage 1 administration.

Time frame:
Baseline, Week 16
Reported as:
Mean · percent change
Percent Change in BMI From Baseline to the End of Stage 1 in Participants ≥18 Years Old, Per Genotype
percent changeStage 1: Setmelanotide (Open-Label)
Overall: Change at Week 16-3.95 ± 4.057
Gene: NRP2, Change at Week 16-1.37 ± 1.804
Gene: PLXNA1, Change at Week 16-1.22 ± 1.576
Gene: PLXNA2, Change at Week 16-4.69 ± 0.913
Gene: PLXNA3, Change at Week 16-9.06
Gene: PLXNA4, Change at Week 16-5.34 ± 6.682
Gene: SEMA3A, Change at Week 16-5.31
Gene: SEMA3D, Change at Week 16-3.57 ± 1.960
Gene: SEMA3E, Change at Week 16-11.23 ± 0.185
Gene: SEMA3F, Change at Week 16-7.58
Gene: SEMA3G, Change at Week 16-4.80 ± 2.810
Gene: PHIP, Change at Week 16-5.11 ± 2.770
Gene: SIM1, Change at Week 16-2.63 ± 3.720
Gene: MAGEL2, Change at Week 16-2.67 ± 2.227
Gene: CREBBP, Change at Week 160.35
Gene: DNMT3A, Change at Week 16-2.45
Gene: HTR2C, Change at Week 16-2.49
Gene: KSR2, Change at Week 16-1.23 ± 3.189
Gene: RPGRIP1L, Change at Week 16-8.64
Gene: TBX3, Change at Week 16-1.70
Gene: TRPC5, Change at Week 16-0.03 ± 2.094
SecondaryMean Change in Body Weight From Baseline to the End of Stage 1 in Participants ≥18 Years Old, Per Genotype

Data are provided for overall and according to participants with specified primary gene. Baseline was defined as the last available measurement taken prior to the start of treatment Stage 1 administration.

Time frame:
Baseline, Week 16
Reported as:
Mean · Kg
Mean Change in Body Weight From Baseline to the End of Stage 1 in Participants ≥18 Years Old, Per Genotype
KgStage 1: Setmelanotide (Open-Label)
Overall, At Baseline136.01 ± 29.815
Overall: Change at Week 16-5.33 ± 5.315
Gene: NRP2, At Baseline147.35 ± 2.098
Gene: NRP2, Change at Week 16-2.03 ± 2.687
Gene: PLXNA1, At Baseline145.30 ± 33.751
Gene: PLXNA1, Change at Week 16-2.33 ± 3.144
Gene: PLXNA2, At Baseline137.94 ± 37.878
Gene: PLXNA2, Change at Week 16-6.50 ± 2.234
Gene: PLXNA3, At Baseline89.73
Gene: PLXNA3, Change at Week 16-8.13
Gene: PLXNA4, At Baseline135.87 ± 24.052
Gene: PLXNA4, Change at Week 16-7.55 ± 8.772
Gene: SEMA3A, At Baseline157.07
Gene: SEMA3A, Change at Week 16-8.33
Gene: SEMA3B, At Baseline97.60
Gene: SEMA3D, At Baseline128.09 ± 49.981
Gene: SEMA3D, Change at Week 16-4.48 ± 0.589
Gene: SEMA3E, At Baseline115.77 ± 19.328
Gene: SEMA3E, Change at Week 16-12.98 ± 1.956
Gene: SEMA3F, At Baseline176.65 ± 10.960
Gene: SEMA3F, Change at Week 16-12.80
Gene: SEMA3G, At Baseline129.41 ± 21.874
Gene: SEMA3G, Change at Week 16-6.59 ± 4.622
Gene: PHIP, At Baseline134.11 ± 36.996
Gene: PHIP, Change at Week 16-5.77 ± 3.504
Gene: SIM1, At Baseline141.25 ± 35.591
Gene: SIM1, Change at Week 16-4.13 ± 4.720
Gene: MAGEL2, At Baseline134.41 ± 20.544
Gene: MAGEL2, Change at Week 16-3.88 ± 3.681
Gene: CREBBP, At Baseline103.60
Gene: CREBBP, Change at Week 160.36
Gene: DNMT3A, At Baseline129.37
Gene: DNMT3A, Change at Week 16-3.17
Gene: HTR2C, At Baseline126.23 ± 9.780
Gene: HTR2C, Change at Week 16-3.40
Gene: KSR2, At Baseline150.16 ± 19.630
Gene: KSR2, Change at Week 16-2.13 ± 4.721
Gene: RPGRIP1L, At Baseline103.47 ± 11.193
Gene: RPGRIP1L, Change at Week 16-8.63
Gene: TBX3, At Baseline119.00 ± 11.644
Gene: TBX3, Change at Week 16-2.17
Gene: TRPC5, At Baseline203.00 ± 25.173
Gene: TRPC5, Change at Week 160.20 ± 4.243
SecondaryPercent Change in Body Weight From Baseline to the End of Stage 1 in Participants ≥18 Years Old, Per Genotype

Data are provided for overall and according to participants with specified primary gene. Baseline was defined as the last available measurement taken prior to the start of treatment Stage 1 administration.

Time frame:
Baseline, Week 16
Reported as:
Mean · percent change
Percent Change in Body Weight From Baseline to the End of Stage 1 in Participants ≥18 Years Old, Per Genotype
percent changeStage 1: Setmelanotide (Open-Label)
Overall: Change at Week 16-3.94 ± 4.052
Gene: NRP2, Change at Week 16-1.37 ± 1.804
Gene: PLXNA1, Change at Week 16-1.22 ± 1.576
Gene: PLXNA2, Change at Week 16-4.69 ± 0.913
Gene: PLXNA3, Change at Week 16-9.06
Gene: PLXNA4, Change at Week 16-5.34 ± 6.682
Gene: SEMA3A, Change at Week 16-5.31
Gene: SEMA3D, Change at Week 16-3.57 ± 1.960
Gene: SEMA3E, Change at Week 16-11.23 ± 0.185
Gene: SEMA3F, Change at Week 16-7.58
Gene: SEMA3G, Change at Week 16-4.80 ± 2.810
Gene: PHIP, Change at Week 16-5.00 ± 2.749
Gene: SIM1, Change at Week 16-2.63 ± 3.720
Gene: MAGEL2, Change at Week 16-2.67 ± 2.227
Gene: CREBBP, Change at Week 160.35
Gene: DNMT3A, Change at Week 16-2.45
Gene: HTR2C, Change at Week 16-2.49
Gene: KSR2, Change at Week 16-1.23 ± 3.189
Gene: RPGRIP1L, Change at Week 16-8.64
Gene: TBX3, Change at Week 16-1.70
Gene: TRPC5, Change at Week 16-0.03 ± 2.094
SecondaryMean Change in BMI Z-score From Baseline to the End of Stage 1 in Participants <18 Years Old, Per Genotype

BMI was calculated using participant's weight and height assessments, using the following formula: BMI = kg/m\^2. The BMI Z-score indicated the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean of a reference population (i.e., healthy, age and sex-matched individuals). A decrease of BMI Z-score indicates a reduction in BMI from Baseline whereas an increase of BMI-Z score indicates an increase in BMI from Baseline. Baseline was defined as the last available measurement taken prior to the start of treatment Stage 1 administration.

Time frame:
Baseline, Week 16
Reported as:
Mean · z-score
Mean Change in BMI Z-score From Baseline to the End of Stage 1 in Participants <18 Years Old, Per Genotype
z-scoreStage 1: Setmelanotide (Open-Label)
Overall, At Baseline2.649 ± 0.3708
Overall: Change at Week 16-0.126 ± 0.1425
Gene: NRP1, At Baseline2.919 ± 0.0848
Gene: NRP1, Change at Week 16-0.000 ± 0.0124
Gene: NRP2, At Baseline2.386
Gene: NRP2, Change at Week 16-0.086
Gene: PLXNA1, At Baseline2.729 ± 0.1250
Gene: PLXNA1, Change at Week 16-0.112 ± 0.0671
Gene: PLXNA2, At Baseline2.955 ± 0.0601
Gene: PLXNA2, Change at Week 16-0.043 ± 0.0707
Gene: PLXNA3, At Baseline2.485 ± 0.4970
Gene: PLXNA3, Change at Week 16-0.234
Gene: PLXNA4, At Baseline2.693 ± 0.3653
Gene: PLXNA4, Change at Week 16-0.063 ± 0.1110
Gene: SEMA3A, At Baseline2.498 ± 0.2057
Gene: SEMA3A, Change at Week 16-0.078
Gene: SEMA3B, At Baseline2.595 ± 0.5201
Gene: SEMA3B, Change at Week 16-0.140
Gene: SEMA3C, At Baseline2.828
Gene: SEMA3C, Change at Week 16-0.037
Gene: SEMA3D, At Baseline2.454
Gene: SEMA3E, At Baseline2.913 ± 0.4705
Gene: SEMA3E, Change at Week 16-0.053 ± 0.0808
Gene: SEMA3F, At Baseline2.847 ± 0.5676
Gene: SEMA3F, Change at Week 16-0.192
Gene: SEMA3G, At Baseline2.826 ± 0.4890
Gene: SEMA3G, Change at Week 16-0.115 ± 0.1020
Gene: PHIP, At Baseline2.457 ± 0.4515
Gene: PHIP, Change at Week 16-0.201 ± 0.1923
Gene: SIM1, At Baseline2.510 ± 0.3107
Gene: SIM1, Change at Week 16-0.182 ± 0.2355
Gene: MAGEL2, At Baseline2.503 ± 0.3034
Gene: MAGEL2, Change at Week 16-0.184 ± 0.1615
Gene: MRAP2, At Baseline2.738
Gene: MRAP2, Change at Week 16-0.019
Gene: KSR2, At Baseline2.831 ± 0.2260
Gene: KSR2, Change at Week 16-0.037 ± 0.0131
Gene: TBX3, At Baseline2.471 ± 0.4419
Gene: TBX3, Change at Week 16-0.254 ± 0.1661
Gene: TRPC5, At Baseline2.078
SecondaryPercent Change in the Weekly Average of the Daily Maximal Hunger Score From Baseline to the End of Stage 1 in Participants ≥12 Years Old, Per Genotype

Daily Hunger Questionnaire for participants ≥12 years of age is self-administered questionnaire and comprises three items. For the assessment of this endpoint, maximal hunger was corresponding to the following question: In the last 24 hours, how hungry did you feel when you were the most hungry? The response was scored separately and averaged on weekly basis. Participants rated their hunger on an 11-point numeric rating scale ranging from 0 to 10 (0 = not hungry at all, and 10 = hungriest possible). Weekly average at Week 16 was defined as average of the available score values within 7 days in Week 16. Baseline was defined as the average of the available score values within 7 days before or on the stage 1 open-label treatment. Results are reported by overall participant results and by specific gene cohort.

Time frame:
Baseline, Week 16
Reported as:
Mean · percent change
Percent Change in the Weekly Average of the Daily Maximal Hunger Score From Baseline to the End of Stage 1 in Participants ≥12 Years Old, Per Genotype
percent changeStage 1: Setmelanotide (Open-Label)
Overall: Change at Week 16-31.13 ± 63.273
Gene: NRP2, Change at Week 16-39.63 ± 1.203
Gene: PLXNA1, Change at Week 16-21.04 ± 10.064
Gene: PLXNA2, Change at Week 16-44.12 ± 37.973
Gene: PLXNA3, Change at Week 16-49.25 ± 4.785
Gene: PLXNA4, Change at Week 16-54.61 ± 31.759
Gene: SEMA3A, Change at Week 16-15.35 ± 5.880
Gene: SEMA3B, Change at Week 16-15.79
Gene: SEMA3C, Change at Week 160.00
Gene: SEMA3D, Change at Week 1636.36
Gene: SEMA3E, Change at Week 16-37.37 ± 23.609
Gene: SEMA3F, Change at Week 16-48.16 ± 24.821
Gene: SEMA3G, Change at Week 1638.70 ± 176.373
Gene: PHIP, Change at Week 16-56.87 ± 19.460
Gene: SIM1, Change at Week 16-25.60 ± 51.690
Gene: MAGEL2, Change at Week 16-39.44 ± 30.215
Gene: DNMT3A, Change at Week 16-23.00
Gene: HTR2C, Change at Week 16-37.29
Gene: KSR2, Change at Week 16-42.17 ± 30.842
Gene: MRAP2, Change at Week 16-47.83
Gene: RPGRIP1L, Change at Week 16-100.00
Gene: TBX3, Change at Week 16-33.67 ± 2.720
Gene: TRPC5, Change at Week 16-16.82 ± 28.427
SecondaryNumber of Participants ≥12 Years Old, Who Achieved a ≥2 Point Reduction From Baseline to the End of Stage 1 in the Weekly Average of the Daily Maximal Hunger Score, Per Genotype

Daily Hunger Questionnaire for participants ≥12 years of age is self-administered questionnaire and comprises three items. For the assessment of this endpoint, maximal hunger was corresponding to the following question: In the last 24 hours, how hungry did you feel when you were the most hungry? The response was scored separately and averaged on weekly basis. Participants rated their hunger on an 11-point numeric rating scale ranging from 0 to 10 (0 = not hungry at all, and 10 = hungriest possible). Weekly average at Week 16 was defined as average of the available score values within 7 days in Week 16. Baseline was defined as the average of the available score values within 7 days before or on the stage 1 open-label treatment. Results are reported by overall participant results and by specific gene cohort.

Time frame:
Baseline, Week 16
Reported as:
Count of participants · Participants
Number of Participants ≥12 Years Old, Who Achieved a ≥2 Point Reduction From Baseline to the End of Stage 1 in the Weekly Average of the Daily Maximal Hunger Score, Per Genotype
ParticipantsStage 1: Setmelanotide (Open-Label)
Overall49
Gene: NRP22
Gene: PLXNA11
Gene: PLXNA23
Gene: PLXNA32
Gene: PLXNA46
Gene: SEMA3A0
Gene: SEMA3B0
Gene: SEMA3C0
Gene: SEMA3D0
Gene: SEMA3E2
Gene: SEMA3F2
Gene: SEMA3G4
Gene: PHIP7
Gene: SIM17
Gene: MAGEL25
Gene: CREBBP0
Gene: DNMT3A0
Gene: HTR2C1
Gene: KSR23
Gene: MRAP20
Gene: RPGRIP1L1
Gene: TBX32
Gene: TRPC51

Adverse events

Collected over Stage 1 : Baseline to Week 16 Stage 2 : Week 16 to Week 44. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Stage 1: Setmelanotide (Open-Label)0/164 (0%)6/164 (3.7%)160/164 (97.6%)
Stage 2: Setmelanotide (Double-Blind)0/35 (0%)0/35 (0%)25/35 (71.4%)
Stage 2: Placebo (Double-Blind)0/14 (0%)0/14 (0%)10/14 (71.4%)
Most frequent serious events
Most frequent serious events
EventStage 1: Setmelanotide (Open-Label)Stage 2: Setmelanotide (Double-Blind)Stage 2: Placebo (Double-Blind)
DepressionPsychiatric disorders2/1640/350/14
GastritisGastrointestinal disorders1/1640/350/14
VomitingGastrointestinal disorders1/1640/350/14
HeadacheNervous system disorders1/1640/350/14
AsthmaRespiratory, thoracic and mediastinal disorders1/1640/350/14
AngioedemaSkin and subcutaneous tissue disorders1/1640/350/14
Most frequent other events
Showing 10 of 264
Most frequent other events
EventStage 1: Setmelanotide (Open-Label)Stage 2: Setmelanotide (Double-Blind)Stage 2: Placebo (Double-Blind)
Skin hyperpigmentationSkin and subcutaneous tissue disorders130/1647/351/14
NauseaGastrointestinal disorders75/1644/350/14
Injection site erythemaGeneral disorders62/1641/352/14
Melanocytic naevusNeoplasms benign, malignant and unspecified (incl cysts and polyps)52/1647/352/14
Injection site pruritusGeneral disorders49/1641/350/14
Injection site indurationGeneral disorders47/1641/352/14
Injection site painGeneral disorders46/1640/351/14
HeadacheNervous system disorders43/1644/350/14
VomitingGastrointestinal disorders41/1643/350/14
FatigueGeneral disorders29/1640/351/14

Baseline characteristics

Safety Analysis Set included all participants who received at least one dose of trial medication.

Age, Continuous
Age, Continuous(years)All Participants
Mean30.2 ± 16.94
Sex: Female, Male
Sex: Female, Male(Participants)All Participants
Female110
Male54
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)All Participants
Hispanic or Latino38
Not Hispanic or Latino124
Unknown or Not Reported2
Race (NIH/OMB)
Race (NIH/OMB)(Participants)All Participants
American Indian or Alaska Native2
Asian2
Native Hawaiian or Other Pacific Islander0
Black or African American16
White128
More than one race0
Unknown or Not Reported16
08

Study locations

36 sites
  • HonorHealth Bariatric Center
    Scottsdale, Arizona 85258, United States
  • InQuest Medical Reseacrh
    Suwanee, Georgia 30071, United States
  • UMass Memorial Medical Center
    Worcester, Massachusetts 01655, United States
  • University of Michigan
    Ann Arbor, Michigan 48105, United States
  • Metro Detroit Endocrinology Center
    Dearborn, Michigan 48126, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Mississippi Center for Advanced Medicine
    Madison, Mississippi 39110, United States
  • Mount Sinai
    New York, New York 10029, United States
  • Columbia University
    New York, New York 10032, United States
  • Ten's Medical Center - Pediatric Endocrinology Clinic
    Staten Island, New York 10308, United States
  • University of North Carolina
    Chapel Hill, North Carolina 27517, United States
  • Geisinger Clinic
    Danville, Pennsylvania 17822, United States
  • The Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • Texas Tech
    Amarillo, Texas 79106, United States
  • Endocrine Associates of Dallas and Plano
    Dallas, Texas 75231, United States
  • Hector Granados PA
    El Paso, Texas 79907, United States
  • Texas Children's Hospital
    Houston, Texas 77030, United States
  • Accurate Clinical Research
    Houston, Texas 77065, United States
  • Rio Grande Valley Endocrine Center
    McAllen, Texas 78503, United States
  • Clinical Trials of Texas
    San Antonio, Texas 78229, United States
  • Javara Research
    The Woodlands, Texas 77382, United States
  • University of Alberta
    Edmonton, Alberta T6G 2E1, Canada
  • Charite - Universitatsmedizin Berlin
    Berlin, Germany
  • Universitaetsklinikum Leipzig
    Leipzig, 04103, Germany
  • Universitaetsklinikum Ulm
    Ulm, 89075, Germany
  • University of Patras School of Medicine
    Pátrai, Greece
  • Chaim Sheba MC, Safra Children's Hospital
    Ramat Gan, 5265602, Israel
  • Erasmus Medisch Centrum
    Rotterdam, 3015 GD, Netherlands
  • Hospital Sant Joan de Deu
    Barcelona, 08950, Spain
  • Hospital Infantil Universitario Nino Jesus
    Madrid, 28009, Spain
  • Hospital Fundación Jimenez Díaz
    Madrid, 28040, Spain
  • Hospital General de Valencia
    Valencia, 46014, Spain
  • Bristol Royal Hospital for Children
    Bristol, United Kingdom
  • University of Cambridge
    Cambridge, United Kingdom
  • London Medical - The London Diabetes Centre
    London, NW1 2PG, United Kingdom
  • University College London Hospitals NHS Foundation Trust
    London, WC1E 6JF, United Kingdom
09

References and documents

Publications

  • Trapp CM, Censani M. Setmelanotide: a promising advancement for pediatric patients with rare forms of genetic obesity. Curr Opin Endocrinol Diabetes Obes. 2023 Apr 1;30(2):136-140. doi: 10.1097/MED.0000000000000798. Epub 2023 Feb 1. PubMed 36722447 ↗
  • Cuda S, Censani M. Progress in pediatric obesity: new and advanced therapies. Curr Opin Pediatr. 2022 Aug 1;34(4):407-413. doi: 10.1097/MOP.0000000000001150. Epub 2022 Jul 5. PubMed 35797460 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2021 to primary completion in Aug 2023, 20 months.

Results were first posted in Oct 2024, 1 year 2 months after primary completion.

Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 20 months is above that.

Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2021
First posted
Jul 15, 2021
StartActual
Nov 30, 2021
Primary completionActual
Aug 4, 2023
CompletionActual
Sep 30, 2024
Results first posted
Oct 24, 2024
Last update
Jul 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04963231
Responsible party
Sponsor
First posted
Jul 15, 2021
Start date
Nov 30, 2021
Primary completion
Aug 4, 2023
Completion
Sep 30, 2024
Results posted
Oct 24, 2024
Last update
Jul 2, 2025

Study contacts

David Meeker, MD
study chair · Rhythm Pharmaceuticals, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Setmelanotide

Start the discussion